denkapparat Operations GmbH acquired a new stake in Chemed Corporation (NYSE:CHE – Free Report) in the 2nd quarter, Holdings Channel reports. The firm acquired 1,370 shares of the company’s stock, valued at approximately $638,000.
Other institutional investors and hedge funds have also made changes to their positions in the company. Monetary Solutions Ltd purchased a new stake in shares of Chemed during the fourth quarter worth approximately $25,000. Los Angeles Capital Management LLC acquired a new position in Chemed during the 4th quarter worth approximately $26,000. BOK Financial Private Wealth Inc. acquired a new position in Chemed during the 4th quarter worth approximately $27,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Chemed in the 2nd quarter valued at approximately $34,000. Finally, Versant Capital Management Inc increased its position in shares of Chemed by 7,500.0% in the 2nd quarter. Versant Capital Management Inc now owns 76 shares of the company’s stock valued at $35,000 after purchasing an additional 75 shares during the last quarter. 95.85% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling at Chemed
In other news, CEO Kevin McNamara sold 2,000 shares of the stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $541.16, for a total transaction of $1,082,320.00. Following the completion of the sale, the chief executive officer owned 70,418 shares in the company, valued at approximately $38,107,404.88. This represents a 2.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Patrick Grace sold 190 shares of the firm’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $532.00, for a total value of $101,080.00. Following the transaction, the director directly owned 3,533 shares in the company, valued at approximately $1,879,556. This represents a 5.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 6,537 shares of company stock worth $3,406,014 over the last three months. 3.33% of the stock is currently owned by corporate insiders.
Chemed Stock Performance
Chemed (NYSE:CHE – Get Free Report) last released its quarterly earnings results on Tuesday, July 28th. The company reported $6.06 EPS for the quarter, beating the consensus estimate of $5.60 by $0.46. The firm had revenue of $673.25 million during the quarter, compared to the consensus estimate of $665.04 million. Chemed had a net margin of 10.60% and a return on equity of 31.77%. Chemed’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $4.27 EPS. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. As a group, equities analysts predict that Chemed Corporation will post 23.18 EPS for the current year.
Chemed Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Thursday, September 3rd. Stockholders of record on Monday, August 17th were issued a $0.70 dividend. The ex-dividend date of this dividend was Monday, August 17th. This is a positive change from Chemed’s previous quarterly dividend of $0.60. This represents a $2.80 dividend on an annualized basis and a dividend yield of 0.5%. Chemed’s dividend payout ratio is currently 14.06%.
Analyst Upgrades and Downgrades
Several research firms have recently issued reports on CHE. Royal Bank Of Canada lifted their price objective on shares of Chemed from $436.00 to $548.00 and gave the stock a “sector perform” rating in a research report on Thursday, July 30th. Weiss Ratings upgraded Chemed from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 17th. Oppenheimer lifted their price target on Chemed from $500.00 to $590.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Wall Street Zen raised Chemed from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Finally, Bank of America reiterated a “neutral” rating on shares of Chemed in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $530.75.
Check Out Our Latest Stock Analysis on CHE
Chemed Profile
Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.
The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.
Further Reading
- Five stocks we like better than Chemed
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHE – Free Report).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.
